Gabrielli G B, Corrocher R, De Sandre G
Int J Clin Pharmacol Ther Toxicol. 1984 Mar;22(3):167-9.
The efficacy of ceftazidime, a new broad-spectrum cephalosporin, active also against Pseudomonas aeruginosa, was tested in 19 patients suffering from severe, nonpulmonary localized or systemic infections, which were associated for the most part with concurrent diseases that often had already been unsuccessfully treated with other antibiotics. The treatment varied from 0.5 to 2 g three times daily by the intramuscular or intravenous routes for a minimum of 6 to a maximum of 16 days. Most of the microorganisms isolated were gram-negative (82.6%). Ceftazidime treatment proved efficacious in 17 of 19 cases (89.4%). No toxic effects were observed on hepatic, renal, and hematologic functions. Only in one case did a transient skin rash appear, which did not necessitate discontinuance of the treatment.
头孢他啶是一种新型广谱头孢菌素，对铜绿假单胞菌也有活性，对19例患有严重非肺部局部或全身感染的患者进行了疗效测试，这些感染大多与并发疾病有关，而这些并发疾病通常已经用其他抗生素治疗无效。治疗方式为每日三次，每次0.5至2克，通过肌肉注射或静脉注射，最少6天，最多16天。分离出的大多数微生物为革兰氏阴性菌（82.6%）。在19例病例中的17例（89.4%）中，头孢他啶治疗证明有效。未观察到对肝、肾和血液学功能的毒性作用。仅在1例中出现了短暂的皮疹，无需停药。
